Drugnews

When will HARMONi-3 read out?

Following Summit Therapeutics’ November 15, 2026 (U.S. time) announcement of an FDA complete response letter for Akeso’s ivonescimab, HARMONi-3 remains a separate first-line lung cancer trial. Summit’s November 4, 2026 guidance expected squamous-cohort primary progression-free survival and early interim overall survival analyses in Q4 2026, followed by non-squamous progression-free survival analysis in H1 2027. These are company expectations rather than guaranteed public readout or approval dates; HARMONi-7 separately compares ivonescimab monotherapy with pembrolizumab in first-line PD-L1-high lung cancer.

Updated

HARMONi-3 company outlook, as of November 4, 2026
MeasureReported resultBasis
Squamous cohortQ4 2026Events for primary PFS analysis
Squamous cohortQ4 2026Early interim OS analysis alongside primary PFS analysis
Non-squamous cohortH1 2027Events for PFS analysis
Timing basisCompany expectationsEvent-driven; analysis timing may change

Ivonescimab after the FDA letter

On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.

November 17, 2026 analysis

Sources

Read the full analysis

FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026